Literature DB >> 28755323

Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis.

Anne Fogli1,2,3,4, Marie-Véronique Demattei5, Laetitia Corset5, Catherine Vaurs-Barrière1,2,3, Emmanuel Chautard6,7, Julian Biau6,7, Jean-Louis Kémény6,8, Catherine Godfraind8,9, Bruno Pereira10, Toufik Khalil11,12, Nathalie Grandin5, Philippe Arnaud1,2,3, Michel Charbonneau13, Pierre Verrelle6,14.   

Abstract

Human malignant gliomas exhibit acquisition of either one of two telomere maintenance mechanisms, resulting from either reactivation of telomerase expression or activation of an alternative lengthening of telomeres (ALT) mechanism. In the present study, we analyzed 63 human malignant gliomas for the presence of ALT-specific extrachromosomal circles of telomeric DNA (C-circles) and measured telomerase expression, telomeric DNA content (Telo/Alu method), and telomeric repeat-containing RNAs (TERRA) levels. We also assessed histomolecular markers routinely used in clinical practice. The presence of C-circles significantly correlated with IDH1/2 mutation, MGMT exon 1 methylation, low Ki-67 immunostaining, increased telomeric DNA content, absence of functional ATRX protein and level of HTERT gene expression. In multivariate analysis, we observed a trend to a correlation between elevated TERRA levels and increased survival. Interestingly, the C-circles assay allowed to detect ALT activation in glioblastomas exhibiting wild-type IDH1/2 and ATRX expression. These results suggest that, after the correlations uncovered here have been confirmed on larger numbers of tumors, telomeric markers might be useful in improving diagnosis. They also point out to the utility of using the specific, sensitive and quantitative C-circle and Telo/Alu assays that can work with as few as 30 ng of tumor DNA.

Entities:  

Keywords:  ATRX expression; Alternative lengthening of telomeres; C-circle assay; Gliomas; Telomeric markers

Mesh:

Substances:

Year:  2017        PMID: 28755323     DOI: 10.1007/s11060-017-2585-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  34 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Presence of alternative lengthening of telomeres mechanism in patients with glioblastoma identifies a less aggressive tumor type with longer survival.

Authors:  Kerrie L McDonald; Julie McDonnell; Alessandra Muntoni; Jeremy D Henson; Monika E Hegi; Andreas von Deimling; Helen R Wheeler; Ray J Cook; Michael T Biggs; Nicholas S Little; Bruce G Robinson; Roger R Reddel; Janice A Royds
Journal:  J Neuropathol Exp Neurol       Date:  2010-07       Impact factor: 3.685

Review 3.  Molecular mechanisms of activity and derepression of alternative lengthening of telomeres.

Authors:  Hilda A Pickett; Roger R Reddel
Journal:  Nat Struct Mol Biol       Date:  2015-11-04       Impact factor: 15.369

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines.

Authors:  T M Bryan; A Englezou; L Dalla-Pozza; M A Dunham; R R Reddel
Journal:  Nat Med       Date:  1997-11       Impact factor: 53.440

6.  Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.

Authors:  Rachel Litman Flynn; Kelli E Cox; Maya Jeitany; Hiroaki Wakimoto; Alysia R Bryll; Neil J Ganem; Francesca Bersani; Jose R Pineda; Mario L Suvà; Cyril H Benes; Daniel A Haber; Francois D Boussin; Lee Zou
Journal:  Science       Date:  2015-01-16       Impact factor: 47.728

7.  Identification of valid endogenous control genes for determining gene expression in human glioma.

Authors:  Simone Kreth; Jens Heyn; Stefan Grau; Hans A Kretzschmar; Rupert Egensperger; Friedrich W Kreth
Journal:  Neuro Oncol       Date:  2010-02-05       Impact factor: 12.300

8.  Telomerase activation in mouse mammary tumors: lack of detectable telomere shortening and evidence for regulation of telomerase RNA with cell proliferation.

Authors:  D Broccoli; L A Godley; L A Donehower; H E Varmus; T de Lange
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

9.  Telomerase-independent paths to immortality in predictable cancer subtypes.

Authors:  Stephen T Durant
Journal:  J Cancer       Date:  2012-01-31       Impact factor: 4.207

10.  Loss of wild-type ATRX expression in somatic cell hybrids segregates with activation of Alternative Lengthening of Telomeres.

Authors:  Kylie Bower; Christine E Napier; Sara L Cole; Rebecca A Dagg; Loretta M S Lau; Emma L Duncan; Elsa L Moy; Roger R Reddel
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

View more
  11 in total

1.  TCGA Pan-Cancer Genomic Analysis of Alternative Lengthening of Telomeres (ALT) Related Genes.

Authors:  Isaac Armendáriz-Castillo; Andrés López-Cortés; Jennyfer García-Cárdenas; Patricia Guevara-Ramírez; Paola E Leone; Andy Pérez-Villa; Verónica Yumiceba; Ana K Zambrano; Santiago Guerrero; César Paz-Y-Miño
Journal:  Genes (Basel)       Date:  2020-07-21       Impact factor: 4.096

2.  Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis.

Authors:  Alejandro Cabrera-Andrade; Andrés López-Cortés; Gabriela Jaramillo-Koupermann; César Paz-Y-Miño; Yunierkis Pérez-Castillo; Cristian R Munteanu; Humbert González-Díaz; Alejandro Pazos; Eduardo Tejera
Journal:  Int J Mol Sci       Date:  2020-02-05       Impact factor: 5.923

3.  The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.

Authors:  Nathalie Grandin; Bruno Pereira; Camille Cohen; Pauline Billard; Caroline Dehais; Catherine Carpentier; Ahmed Idbaih; Franck Bielle; François Ducray; Dominique Figarella-Branger; Jean-Yves Delattre; Marc Sanson; Patrick Lomonte; Delphine Poncet; Pierre Verrelle; Michel Charbonneau
Journal:  Acta Neuropathol Commun       Date:  2019-11-09       Impact factor: 7.578

4.  Detection of alternative lengthening of telomeres mechanism on tumor sections.

Authors:  Eloïse Claude; Guillaume de Lhoneux; Christophe E Pierreux; Etienne Marbaix; Maëlle de Ville de Goyet; Cécile Boulanger; An Van Damme; Bénédicte Brichard; Anabelle Decottignies
Journal:  Mol Biomed       Date:  2021-10-20

5.  Reliable assessment of telomere maintenance mechanisms in neuroblastoma.

Authors:  Alina Meeser; Christoph Bartenhagen; Lisa Werr; Anna-Maria Hellmann; Yvonne Kahlert; Nadine Hemstedt; Peter Nürnberg; Janine Altmüller; Sandra Ackermann; Barbara Hero; Thorsten Simon; Martin Peifer; Matthias Fischer; Carolina Rosswog
Journal:  Cell Biosci       Date:  2022-09-24       Impact factor: 9.584

6.  Measurement of Telomere Length in Colorectal Cancers for Improved Molecular Diagnosis.

Authors:  Eric Le Balc'h; Nathalie Grandin; Marie-Véronique Demattei; Serge Guyétant; Anne Tallet; Jean-Christophe Pagès; Mehdi Ouaissi; Thierry Lecomte; Michel Charbonneau
Journal:  Int J Mol Sci       Date:  2017-08-29       Impact factor: 5.923

Review 7.  Telomere Maintenance Mechanisms in Cancer.

Authors:  Tiago Bordeira Gaspar; Ana Sá; José Manuel Lopes; Manuel Sobrinho-Simões; Paula Soares; João Vinagre
Journal:  Genes (Basel)       Date:  2018-05-03       Impact factor: 4.096

Review 8.  Current understanding of extrachromosomal circular DNA in cancer pathogenesis and therapeutic resistance.

Authors:  Yuanliang Yan; Guijie Guo; Jinzhou Huang; Ming Gao; Qian Zhu; Shuangshuang Zeng; Zhicheng Gong; Zhijie Xu
Journal:  J Hematol Oncol       Date:  2020-09-14       Impact factor: 17.388

Review 9.  ALT Positivity in Human Cancers: Prevalence and Clinical Insights.

Authors:  Danny MacKenzie; Andrea K Watters; Julie T To; Melody W Young; Jonathan Muratori; Marni H Wilkoff; Rita G Abraham; Maria M Plummer; Dong Zhang
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

10.  Prevalence and potentially prognostic value of C-circles associated with alternative lengthening of telomeres in canine appendicular osteosarcoma.

Authors:  Ludmila Bicanova; Theresa Kreilmeier-Berger; Martin Reifinger; Klaus Holzmann; Miriam Kleiter
Journal:  Vet Comp Oncol       Date:  2020-12-08       Impact factor: 2.613

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.